Different Risk Relations with Smoking for Non-small-cell lung Cancer: Comparison of TP53 and TP73 Genotypes

Asian Pacific Journal of Cancer Prevention

Volumn 4, Issue 2, 2003, Pages 107-112

  Hiraki, Akio ^a   Matsuo, Keitaro ^b,c   Hamajima, Nobuyuki ^b   Ito, Hidemi ^b   Hatooka, Shunzo ^b   Suyama, Motokazu ^b   Mitsudomi, Tetsuya ^b   Tajima, Kazuo ^b  

^a NATIONAL SANYO HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Aichi Cancer Center Hospital ^*  (United States)

Author keywords

Non small cell lung cancer p53 p73 polymorphism smoking gene environment interaction

Indexed keywords

DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; RISK FACTOR; SMOKING; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEINS;

EID: 0142214542     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Birgander R, Sjalander A, Rannug A, et al (1995). P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis, 16, 2233-6.
2. Davis PK and Dowdy SF (2001). p73. Int J Biochem Cell Biol, 33, 935-9.
3. Fan R, Wu MT, Miller D, et al (2000). The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 9, 1037-42.
4. Hamajima N, Matsuo K, Saito T, et al (2001a). Gene-environment interaction and polymorphism studies of cancer risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II). Asian Pac J Cancer Prev, 2, 99-108.
5. Hamajima N, Matsuo K, Suzuki T, et al (2002). No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett, 181, 81-5.
6. Hamajima N, Matsuo K, Yuasa H (2001b). Adjustment of prognostic effects in prevalent case-control studies on genotype. J Epidemiol, 11, 204-10.
7. Hamajima N, Saito T, Matsuo K, et al (2000). Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res, 91, 865-8.
8. Ito H, Hamajima N, Takezaki T, et al (2002). A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. J Epidemiol, 12, 258-65.
9. Jin X, Wu X, Roth JA, et al (1995). Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis, 16, 2205-8.
10. Kaghad M, Bonnet H, Yang A, et al (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90, 809-19.
11. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993). Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis, 14, 1085-9.
12. Kumimoto H, Hamajima N, Nishimoto Y, et al (2002). L-myc genotype is associated with different susceptibility to lung cancer in smokers. Jpn J Cancer Res, 93, 1-5.
13. Liu G, Miller DP, Zhou W, et al (2001). Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res, 61, 8718-22.
14. Mai M, Yokomizo A, Qian C, et al (1998). Activation of p73 silent allele in lung cancer. Cancer Res, 58, 2347-9.
15. Marin MC, Jost CA, Brooks LA, et al (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet, 25, 47-54.
16. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T (2000). Prognostic significance of p53 alterations in patients with nonsmall cell lung cancer: a meta-analysis. Clin Cancer Res, 6, 4055-63.
17. Murata M, Tagawa M, Kimura M, et al (1996). Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis, 17, 261-4.
18. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T (1998). Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res, 58, 1380-3.
19. Peters MA, Janer M, Kolb S, et al (2001). Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate, 48, 292-6.
20. Pierce LM, Sivaraman L, Chang W, et al (2000). Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev, 9, 1199-204.
21. Ryan BM, McManus R, Daly JS, et al (2001). A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer, 85, 1499-503.
22. Tada M, Furuuchi K, Kaneda M, et al (2001). Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis, 22, 515-7.
23. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
24. To-Figueras J, Gene M, Gomez-Catalan J, et al (1996). Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev, 5, 337-42.
25. Tominaga S and Oshima A (1999). Cancer mortality and morbidity statistics. Gann Monogr Cancer Res Vol.47, Tokyo.
26. Walker KK and Levine AJ (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A, 93, 15335-40.
27. Wang XQ, Ongkeko WM, Lau AW, Leung KM, Poon RY (2001). A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res, 61, 1598-603.
28. Weston A, Perrin LS, Forrester K, et al (1992). Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev, 1, 481- 3.
29. Yang Q, Khoury MJ, Flanders WD (1997). Sample size requirements in case-only designs to detect gene-environment interaction. Am J Epidemiol, 146, 713-20